The 2026 Healthtech Messaging Index
Formation Bio
formation.bio·scored August 23, 2026
12/38
Weak
The signal is faint. Most of this page is about Formation Bio, not the buyer, and AI has little it can repeat. There's a lot of room to move.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for AI-driven clinical-stage drug development and licensing partner, it named:
Buyer we put in the prompt: Business development or licensing executive at a pharma company, biotech, or university tech transfer office looking to out-license or co-develop clinical-stage drug assets. Both the buyer and the category were inferred from Formation Bio’s homepage alone. The model had no web access.
Formation Bio was not on the list.
A buyer who asked AI this question got 8 names and moved on. Formation Bio never came up.
We asked AI who it recommends for "Business development or licensing executive at a pharma company, biotech, or university tech transfer office looking to out-license or co-develop clinical-stage drug assets" looking for "AI-driven clinical-stage drug development and licensing partner". It named Recursion Pharmaceuticals, Insilico Medicine, BenevolentAI, Exscientia, Relay Therapeutics. You did not appear. AI can't recommend what it can't clearly understand.
Overall assessment
Formation Bio's single biggest strength is a genuinely differentiated business model ... acquiring and developing clinical-stage assets with a tech-native platform ... that at least points toward something concrete. The single biggest gap is complete absence of buyer-facing specificity: no ICP is named, no cost of inaction is stated, no social proof or partner evidence exists, and the AI and platform claims are pure label with zero mechanism, leaving the page unable to convert or be cited with confidence by any AI or human evaluator.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
04ICP Clarity
“No mention of buyer role, company size, stage, or vertical anywhere on the page.”
The page never specifies whether it is speaking to pharma business development executives, biotech founders, university tech transfer offices, or investors ... the ICP is completely invisible.
All 19 signals, scored 0 to 2.
Total 12/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“The pharma company of the future. Our mission is to bring new treatments to patients faster and more efficiently.”
The hero communicates direction but not who the buyer is, what specific problem is solved for them, or any distinct point of view ... 'faster and more efficiently' is too generic to orient a stranger in 7 seconds.
- 1
02Rebellion / Movement
“The existing drug development ecosystem can't keep up with the pace of scientific discovery.”
There is a named status quo being pushed against ... a broken development ecosystem ... but no named enemy, no indictment of a specific industry practice or incumbent by name, and no manifesto framing it as a movement.
- 1
03Owned Language & Category
“tech-driven, AI-native pharma company" and "radical efficiency throughout the drug development lifecycle”
The page hints at a frame ('tech-driven, AI-native pharma') but does not coin a proprietary term, name a category, or own a framework an AI could uniquely attribute to Formation Bio.
- 0
04ICP Clarityweakest
“No mention of buyer role, company size, stage, or vertical anywhere on the page.”
The page never specifies whether it is speaking to pharma business development executives, biotech founders, university tech transfer offices, or investors ... the ICP is completely invisible.
- 1
05Problem Leadership
“The drug development bottleneck... drug development costs have exponentially increased, creating a widening gap”
There is a problem section, but it reads like an industry analyst summary rather than leading with the buyer's lived pain in their own language before introducing Formation Bio's solution.
- 1
06Solution Clarity
“Formation Bio acquires clinical-stage drugs from pharma, universities, and biotech and develops them faster and more efficiently”
A visitor can form a rough one-sentence summary, but the mechanism ... what 'tech-driven platform' actually does ... is never made concrete enough to repeat with confidence.
- 0
07Cost of Inaction
“No mention of cost of delay, missed milestones, lost value, or what happens if a partner does not act.”
The page never names the price a potential partner or licensor pays for continuing with the status quo ... there is zero urgency or consequence language directed at a buyer.
- 1
08Promised Land
“reaching inflection points earlier than industry norms while also accelerating access to new potential treatments for patients”
An 'after state' is implied ... faster inflection points, more patients reached ... but it is described abstractly with no specific timeline, delta, or vivid picture of life after partnering with Formation Bio.
Trust Signal
4 signals
- 1
09Proof & Evidence
“Our team and advisors have collectively worked on 45+ approved drugs”
One concrete number appears (45+ approved drugs) but there are no before/after deltas, no trial timelines compressed, no cost savings quantified, and no named outcomes from actual programs.
- 0
10Social Proof
“No customer logos, testimonials, named case studies, or partner quotes anywhere on the page.”
The page contains zero social proof ... no named partners, no deal announcements cited, no quotes from anyone outside Formation Bio.
- 1
11Authority & Credibility
“Mike Ehlers joins Formation Bio as Chief Scientific Officer and Head of R&D" and "45+ approved drugs”
A high-profile CSO hire signals credibility, and the 45+ approved drugs stat helps, but no founder credentials, original research, frameworks, or awards are presented on the homepage itself.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, CROs, in-house development teams, or 'do nothing' option anywhere.”
The page never acknowledges what buyers would otherwise do ... hire a CRO, do development in-house, or partner with a different acquirer ... making Formation Bio appear unaware of its competitive landscape.
AI Signal
6 signals
- 1
13Customer Focus
“striving to meet critical unmet patient need" vs. "our proprietary tech-driven drug development platform”
The page oscillates between the patient as end beneficiary and Formation Bio's own platform capabilities ... the direct buyer/partner is rarely centered as protagonist, so the company is more often the subject of sentences than the customer.
- 1
14AI-Parmesan Index
“tech-driven, AI-native platform" and "AI advancements”
AI is invoked as a label ('AI-native') without any mechanistic description of what the AI actually does in drug development, making it feel sprinkled rather than substantive ... though it stops short of being egregious AI-washing.
- 1
15LLM Quotability
“Formation Bio acquires clinical-stage drugs from pharma, universities, and biotech and develops them faster and more efficiently by leveraging our proprietary tech-driven drug development platform.”
This sentence is structurally quotable but too vague and generic for an LLM to use as a differentiating citation ... it lacks the specificity, numbers, or named mechanism that would make it stand out in an AI recommendation.
- 0
16Copyright Freshness
“No visible dates on blog posts displayed on homepage, no copyright year visible in scraped content, only a CSO hire announcement with no date shown.”
The homepage provides no visible recency signals ... no dated case studies, no timestamped news items, and no copyright year ... leaving AI engines with nothing to anchor freshness.
- 1
17Entity Distinctiveness
“tech-driven, AI-native pharma company" that "acquires clinical-stage drugs from pharma, universities, and biotech”
The acquirer-plus-developer model is somewhat distinctive, but the language is generic enough that swapping the logo for another AI-pharma company would leave the description largely intact ... an AI could not confidently attribute this to Formation Bio alone.
- 0
18AI Recommendation Check
“AI's picks: Recursion Pharmaceuticals, Insilico Medicine, BenevolentAI, Exscientia, Relay Therapeutics, Absci. You were not named.”
We asked AI who it recommends for "Business development or licensing executive at a pharma company, biotech, or university tech transfer office looking to out-license or co-develop clinical-stage drug assets" looking for "AI-driven clinical-stage drug development and licensing partner". It named Recursion Pharmaceuticals, Insilico Medicine, BenevolentAI, Exscientia, Relay Therapeutics. You did not appear. AI can't recommend what it can't clearly understand.
Conversion Signal
1 signal
- 0
19Path & CTA Clarity
“Partner With Us" and "Contact Us" links exist but no numbered process, no primary vs. secondary CTA distinction, no steps shown.”
There is a vague 'Partner With Us' section with a Contact Us link but no visible path, no numbered steps, and no soft secondary CTA ... the conversion architecture is essentially absent.
Your move
Think Formation Bio’s score is wrong? Good. Let’s look at it together.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Formation Bio the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.